ONCAlert | AstraZeneca: Pioneers in Ovarian Cancer

Lung Latest NewsMORE >>

Roy S. Herbst, MD, PhD, discusses how the therapeutic paradigm will continue to evolve in the next few years for non–small cell lung cancer, with an increased emphasis on rational combinations and biomarkers.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.